{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-001318","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.534245+00:00","generated_at":"2026-05-30T03:42:09.711693+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcturus Q3 net loss narrows to $6.9M; $25M milestone from KOSTAIVE first sale in Japan","bullets":["Q3 revenue $41.7M vs $45.2M YoY, down on lower CSL milestones; net loss $6.9M ($0.26/sh) vs $16.2M ($0.61/sh).","Cash $294.1M; runway extended through Q1 2027. Total $462.1M in upfront and milestone payments from CSL to date.","$25M commercial milestone triggered by first sale of KOSTAIVE in Japan by Meiji Seika Pharma in September.","ARCT-032 CF and ARCT-810 OTC deficiency Phase 2 interim proof-of-concept data expected in first half of 2025.","European CHMP opinion for KOSTAIVE expected December 2024; U.S. BLA filing planned in H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-001318","json":"https://secwatch.observer/filing/0001193805-24-001318.json","markdown":"https://secwatch.observer/filing/0001193805-24-001318.md","text":"https://secwatch.observer/filing/0001193805-24-001318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524001318/0001193805-24-001318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524001318/e663993_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:42:09.711693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}